Teva Pharmaceutical

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Teva Pharmaceutical reports robust Q4 earnings, eyes biosimilar growth

Teva Pharmaceutical's Q4 2022 performance showcased revenue growth, strong product momentum, and strategic initiatives in biosimilars and legal settlements. While challenges in debt reduction and market dynamics persist, the company's focus on growth opportunities and financial targets provides a positive outlook for stakeholders.

Teva Pharmaceutical reports revenue growth amidst biosimilar setbacks and opportunities

Teva's Q1 2023 showcased revenue growth, particularly in innovative products like AUSTEDO and AJOVY.
Despite challenges in the biosimilar pipeline and financial losses, the company remains focused on strategic initiatives.
Opportunities lie in UZEDY's market potential and capital allocation for growth and profitability.
Gross margin pressures and legal settlements add complexity to Teva's path forward, requiring careful management.

Teva Pharmaceutical reports Q2 growth, navigates challenges, eyes expansion

Teva Pharmaceutical's Q2 2023 earnings call highlighted revenue growth, operational strength, and commitment to ESG goals, despite facing GAAP losses and operational challenges.
With a focus on debt reduction, increased revenue outlook, and strategic opportunities in biosimilars and new markets, Teva aims to drive long-term growth and financial stability.
Analysts' questions on patient outreach, asset divestiture, and EU entry underscore areas for improvement, while progress on AUSTEDO and UZEDY reception signal positive momentum.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

LOS ANGELES--(BUSINESS WIRE)---- $TEVA #TEVA--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Teva Pharmaceuticals Industries Limited.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Teva Pharmaceuticals Industries Limited and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Teva Pharmaceuticals Industries Limited (NYSE: TEVA) between October 29, 2015 and August 18, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Teva investors under the federal securities laws. To join the Teva class action, go to http://www.rosenlegal.com/cases-register-1956.html or call Phillip Kim

TEVA EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Teva Pharmaceuticals Industries Limited – TEVA

NEW YORK, Sept. 23, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Teva Pharmaceuticals Industries Limited ("Teva" or the "Company") (NYSE: TEVA) and certain of its officers. The class action, filed in United States District Court for the...

Pomerantz Law Firm Announces the Filing of a Class Action against Teva Pharmaceuticals Industries Limited and Certain Officers -  TEVA

AbbVie

Intel

Micron Technology

Seagate Technology Holdings PLC

Walgreens

Western Digital

The stock market may have forgotten about these seven undervalued stocks, but you can pick them up now on the cheap. 
The post 7 Undervalued Stocks With Massive Potential appeared first on InvestorPlace.

7 Undervalued Stocks With Massive Potential

Flex

Fluor

Hewlett Packard

ICICI Bank Ltd.

Limelight Networks

Zynga

Price-to-earnings are one way to find value but there are cheap stocks to buy based on stock price, from technology to manufacturing.
The post 7 Cheap Stocks to Buy Under $10 appeared first on InvestorPlace.

7 Cheap Stocks to Buy Under $10

U.S. Bancorp

Wells Fargo

These stocks haven't been this cheap in a long time.

3 Bargain-Bin Buffett Stocks to Buy Right Now

Amazon

Barrick Gold

Kroger

Snowflake

Warren Buffett's investing acumen is legendary -- but he's not behind every stock in Berkshire Hathaway's portfolio.

5 "Buffett Stocks" Buffett Didn't Actually Buy

JERUSALEM & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Neuroscience, Inc.

Teva to Present New Data at The MDS Virtual Congress 2020 and Psych Congress 2020 Virtual Experience Evaluating Long-Term Treatment with AUSTEDO® (deutetrabenazine) Tablets

Teva to Present New Data on AUSTEDO® (deutetrabenazine) Tablets at the MDS Virtual Congress 2020 and Psych Congress 2020 Virtual Experience

One week ago, the DOJ charged Teva for overcharging customers in an alleged "price-fixing conspiracy."

Teva Charged In Criminal Antitrust Investigation: What It Means

Advanced Semiconductor Engineering

Ford Motor Company

Himax Tech

Newell Brands

Teradata

Investors have many cheap stocks to buy, using widely-followed metrics or by looking at those lacking institutional interest.

7 Cheap Stocks for the Cash-Strapped Investor

Mallinckrodt PLC

The proposed law now goes to Gov. Gavin Newsom for his signature.

California Assembly Passes Generic-Drug Cost-Reduction Bill

On Tuesday, the Wall Street Journal reported the U.S. Justice Department has indicted Teva Pharmaceutical Industries Ltd (NYSE: TEVA), alleging the company participated in three different drug price-fixing conspiracies.

Teva Analyst Estimates $1B In Price-Fixing Liability Following DOJ Indictment

Shares of generic drugmaker Teva Pharmaceutical Industries Ltd (TLV: TEVA) erased early morning losses by Wednesday afternoon despite the generic drugmaker’s U.S. business coming under legal scrutiny.

Teva’s U.S. business indicted, shares gain anyways

Shares of Teva Pharmaceutical Industries Ltd. TEVA, +2.46% were up 1.6% in trading on Wednesday after the drugmaker issued a statement saying it is "deeply disappointed" that the U.S.

Teva's stock rises as the drugmaker defends against price-fixing allegations

The company is hit with three charges in the DOJ's ongoing probe; penalties could total hundreds of millions of dollars.

Teva Pharmaceutical Indicted on Charges of Generic Drugs Price-Fixing

Teva (TEVA) has been indicted on charges of conspiring with other generic drugmakers to raise prices for generic drugs.

Teva Stock Down on Charges of Illegal Generic Price Fixing

The U.S. Justice Department charged Teva Pharmaceutical on Tuesday with conspiring with competitors to raise prices for generic drugs.

U.S. charges Teva in generic drugs price-fixing probe

The Department of Justice on Tuesday indicted Teva Pharmaceutical Industries Ltd’s (NYSE: TEVA) United States unit for conspiring to fix prices, rig bids, and colluding with other companies to allocate customers for generic drugs.

US Indicts Teva Pharmaceutical In Generic Drug Price-Fixing Case

TEL AVIV & PARSIPPANY, N.J.--(BUSINESS WIRE)--Today Teva Pharmaceutical Industries Ltd.

Statement in Response to News of the Indictment of Teva USA

The charges are related to a years-long federal investigation into price fixing by generic drug makers.

Pharma Giant Teva Charged With Price-Fixing

Sepehr Sarshar, the founder and former CEO of Auspex Pharmaceuticals, allegedly helped his friends and family rake in more than $700 million in illegal profits by tipping them off to the sale before it happened.

Pharma Founder Charged In Insider Trading Case Over $3.5 Billion Sale To Teva

The U.S. Justice Department is preparing to charge Teva Pharmaceutical Industries Ltd with conspiring with competitors to raise prices for generic drugs, according to a person familiar with the matter.

U.S. to charge Teva in generic drugs price-fixing probe: source

Teva Pharmaceutical Industries (NYSE: TEVA) shares are trading lower on Tuesday due to the U.S.

Why Teva's Stock Is Trading Lower Today

Annaly Capital

When investors pick stocks whose market capitalization is more than $10 billion and whose price-book ratio stands below 1.5, they increase their chance to discover value stocks.

A Trio of Low Price-Book Ratio Stocks to Consider

News for Teva Pharmaceutical Stock (TEVA)